News Medical on MSN4h
MHRA greenlights donanemab for early stage Alzheimer’s diseaseThe Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
3don MSN
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...
On Wednesday, U.K. regulators approved Eli Lilly And Co’s (NYSE:LLY) donanemab, an injection for intravenous infusion to ...
Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback